{
  "resourceType": "ValueSet",
  "id": "2.16.840.1.113883.3.1444.5.226",
  "meta": {
    "versionId": "12",
    "lastUpdated": "2022-03-02T18:03:26.000-05:00"
  },
  "url": "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.5.226",
  "version": "20210320",
  "name": "Immunotherapy Administration",
  "status": "active",
  "date": "2022-03-03T18:46:01-05:00",
  "publisher": "American Society of Clinical Oncology Steward",
  "compose": {
    "include": [
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.177"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.175"
        ]
      },
      {
        "valueSet": [
          "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.1444.3.174"
        ]
      }
    ]
  },
  "expansion": {
    "identifier": "urn:uuid:70d6711d-94d7-4833-91ef-4fd7ce71dfc3",
    "timestamp": "2022-06-10T08:41:16-04:00",
    "total": 22,
    "offset": 0,
    "parameter": [
      {
        "name": "count",
        "valueInteger": 1000
      },
      {
        "name": "offset",
        "valueInteger": 0
      }
    ],
    "contains": [
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "0540T",
        "display": "Chimeric antigen receptor T-cell (CAR-T) therapy; CAR-T cell administration, autologous"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "180223008",
        "display": "Intravenous immunotherapy (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "180244008",
        "display": "Intramuscular immunotherapy (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "180256009",
        "display": "Subcutaneous immunotherapy (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "589631000119102",
        "display": "Intravenous radioimmunotherapy using monoclonal antibodies (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "60827006",
        "display": "Lymphokine activated killer cell therapy (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "64644003",
        "display": "Immunotherapy for cancer (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "72255009",
        "display": "Interleukin-2 therapy (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "76334006",
        "display": "Immunotherapy (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "84501003",
        "display": "Cytokine therapy (procedure)"
      },
      {
        "system": "http://snomed.info/sct",
        "version": "http://snomed.info/sct/731000124108/version/20220301",
        "code": "870387009",
        "display": "Immune checkpoint inhibitor therapy (procedure)"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96365",
        "display": "Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96366",
        "display": "Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96372",
        "display": "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96374",
        "display": "Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96401",
        "display": "Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96409",
        "display": "Chemotherapy administration; intravenous, push technique, single or initial substance/drug"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96413",
        "display": "Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96415",
        "display": "Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)"
      },
      {
        "system": "http://www.ama-assn.org/go/cpt",
        "version": "2021",
        "code": "96416",
        "display": "Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "Q2041",
        "display": "Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"
      },
      {
        "system": "http://www.nlm.nih.gov/research/umls/hcpcs",
        "version": "2022",
        "code": "Q2042",
        "display": "Tisagenlecleucel, up to 600 million car-positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose"
      }
    ]
  }
}